Aptamer-mediated targeted approach to disrupt oncogenic HSP90α

Key Points

• Disruption of oncogenic hsp90α leads to reduced tumor cell viability, indicating therapeutic potential.
• Significant reduction in cell proliferation observed with 70% less viability in treated cells compared to controls.
• Targeted therapy utilizing aptamers was employed to evaluate impacts on oncogenic pathways using in vitro models.
• Findings highlight a promising strategy for cancer treatment, warranting further investigation in clinical contexts.